Literature DB >> 20446905

Molecular modeling of cytochrome P450 and drug metabolism.

Jing-Fang Wang1, Kuo-Chen Chou.   

Abstract

The cytochrome P450 family is a large and diverse group of hemoproteins that are located in virtually all types of organism, such as bacteria, eukaryotes and even Archaea. These proteins are found throughout the body, however the highest concentrations are associated with liver. As the Human Genome Project completed, there are 57 genes and more than 59 pseudogenes divided among 18 families of CYP genes and 43 subfamilies have been detected. In humans, CYPs are the major enzymes involved in drug metabolism and bioactivation, accounting for almost 75% of the total drug metabolism. The variability in drug metabolisms that are mainly induced by the CYP polymorphisms is reflected on the differences of the maximal plasma concentrations, half lives of some drugs and their clearance. Besides, it can also lead to adverse drug reactions that are considered as a major factor in drug toxicity. So, the genotype-activity relationships of the CYP proteins have become a hot topic in recent years. It is important to further understand why a certain genotype influences enzyme activity and how to predict more structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20446905     DOI: 10.2174/138920010791514180

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  9 in total

1.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Exploration of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations.

Authors:  Jing-Fang Wang; Pei Hao; Yi-Xue Li; Jian-Liang Dai; Xuan Li
Journal:  J Mol Model       Date:  2011-11-25       Impact factor: 1.810

3.  A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution.

Authors:  Nicolas A Stewart; Shama C Buch; Thomas P Conrads; Robert A Branch
Journal:  Analyst       Date:  2010-11-25       Impact factor: 4.616

4.  Insights from modeling the 3D structure of New Delhi metallo-β-lactamse and its binding interactions with antibiotic drugs.

Authors:  Jing-Fang Wang; Kuo-Chen Chou
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

5.  Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1.

Authors:  Jing-Fang Wang; Kuo-Chen Chou
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

6.  An overview of the evidence and mechanisms of herb-drug interactions.

Authors:  Pius S Fasinu; Patrick J Bouic; Bernd Rosenkranz
Journal:  Front Pharmacol       Date:  2012-04-30       Impact factor: 5.810

7.  HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells.

Authors:  Hongming Liu; Guiyu Lou; Chongyi Li; Xiaodong Wang; Arthur I Cederbaum; Lixia Gan; Bin Xie
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

8.  In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate.

Authors:  Shaheed Ur Rehman; Min Sun Choi; In Sook Kim; Zengwei Luo; Yongbo Xue; Guangming Yao; Yonghui Zhang; Hye Hyun Yoo
Journal:  Molecules       Date:  2016-06-18       Impact factor: 4.411

9.  Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy.

Authors:  Huasheng Huang; Xiwen Liao; Guangzhi Zhu; Chuangye Han; Xiangkun Wang; Chengkun Yang; Xin Zhou; Tianyi Liang; Ketuan Huang; Tao Peng
Journal:  Pharmgenomics Pers Med       Date:  2022-03-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.